Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are myeloproliferative neoplasms (MPN) and are characterized by mutually exclusive JAK2, CALR and MPL mutations

Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with MPN

JAK2V617F mutation is the major contributory factor for the pathogenesis of thrombosis in MPN

Pathogenesis of blood clotting activation in these diseases is multifactorial, and involves various abnormalities of hemostatic cells